Publications by authors named "R L Baehner"

Claim this Profile
C
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.
Irene M Kang, Jamie K Forschmiedt, Michelle M Loch, Danika L Lew, William E Barlow, Rick Baehner

JAMA Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trial.
Frédérique Penault-Llorca, Amelie Lusque, Thomas Filleron, Kevin Tran, Lili Du, Rick Baehner

Eur J Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.
Lajos Pusztai, Jess R Hoag, Kathy S Albain, William E Barlow, Salomon M Stemmer, Rick Baehner

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN.
Gilda Schmidt, Oleg Gluz, Matthias Christgen, Mattea Reinisch, Sherko Kümmel, Rick Baehner

Breast Cancer Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay.
Hao-Kuen Lin, Thuy Can, Adriana Kahn, Cynthia A Flannery, Jess Hoag, Rick Baehner

Oncologist· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis